Back to all news

AI Enables Safe 75% Gadolinium Reduction in Breast MRI Without Losing Sensitivity

AuntMinnieIndustry

AI-enhanced breast MRI with a 75% reduced gadolinium dose maintained diagnostic sensitivity comparable to full-dose protocols.

Key Details

  • 1Single-center study with 20 female participants having biopsy-proven malignancies or high-risk indications.
  • 2Low-dose (0.025 mmol/kg) MRI scans with AI were compared to standard-dose (0.1 mmol/kg) with/without AI.
  • 3Diagnostic sensitivity with low-dose + AI was 83.3% (p=1 vs. standard), accuracy was 74.5% vs. 69.5% (standard) and 65.5% (standard+AI).
  • 498 lesions detected; 12 were biopsy-proven malignancies; high NPVs (93-94%) across all protocols.
  • 5AI-assisted low-dose MRI had the highest PPV (50%) and substantial interreader agreement (kappa 0.65-0.74).
  • 6Study was small and lacked long-term outcome data; funded by Bracco.

Why It Matters

Gadolinium retention and cost are growing concerns in breast imaging. This study shows that AI-powered image enhancement could allow safer, lower-dose protocols without compromising cancer detection, marking a significant step for both patient safety and clinical feasibility.

Ready to Sharpen Your Edge?

Subscribe to join 7,500+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.